TrueBlue TBI
TrueBlue FY 2023: net loss $14.2M; diluted EPS −$0.45
- Form
- 10-K
- Filed
- Period
- Importance
- Notable
- Accession
- 0000768899-24-000043
- Document
- 10-K
- Exhibit 4.1
- Description of securities
- Exhibit 10.26
- Form restricted share award notice
- Exhibit 10.27
- Form performance share unit award notice
- Exhibit 10.28
- Form restricted share award notice
- Exhibit 10.29
- Form performance share unit award notice
- Exhibit 10.30
- Form restricted share award notice
- Exhibit 10.31
- Form performance share unit award notice
- Exhibit 10.32
- Executive separation agreement
Key figures from this report
These are the numbers TrueBlue reported for the year ended Dec 31, 2023, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.
- Net income−$14.2M−123% from $62.3M in FY 202210-K income statement, on EDGAR
- Diluted EPS−$0.45−124% from $1.86 in FY 202210-K income statement, on EDGAR
- Cash and cash equivalents$61.9M−14% from $72.1M in FY 202210-K balance sheet, on EDGAR
- Cash from operations$34.8M−71% from $120.5M in FY 202210-K cash flow statement, on EDGAR
Similar companies
Companies of similar size in SIC 7363 and related industry codes: the same peer list as the financial tables.
- Heidrick & Struggles International HSII
- Kelly Services KELYA public float $364M, Jun 29, 2025
- Cross Country Healthcare CCRN public float $393M, Jun 30, 2025
- RCM Technologies RCMT public float $99M, Jun 27, 2025
- Circle8 Group ATLN public float $98M, Jun 30, 2025